Cannabidiol (CBD) “appears to be relatively safe for the treatment of obesity-induced heart disease, as it has anti-inflammatory and partially antioxidative properties”, says newly published research.
The study “explored the potential protective influence of cannabidiol (CBD) on myocardial inflammation state, with a special focus on arachidonic acid (AA), and oxidative balance in lipid overload conditions”. Research was conducted at the Medical University of Bialystok.
The 7-week experiment was conducted on male rats receiving standard or high-fat diet (HFD) with intraperitoneal CBD injections for the last 14 days. Results “revealed that CBD increased n-3 PUFAs activity in phospholipid and triacylglycerol fractions, and decreased AA content in the HFD group, especially in the phospholipid pool.”
Simultaneously, CBD “decreased the expression of nuclear factor kappa B, cyclooxygenase-1, and -2, resulting in the reduction of prostaglandin E2 and the increment of prostaglandin I2”, says the study. “CBD appears to be relatively safe for the treatment of obesity-induced heart disease, as it has anti-inflammatory and partially antioxidative properties.”
Researchers note that “the therapeutic properties of CBD have been demonstrated in extensive studies revealing a reduction of inflammation state and oxidative stress, which are the basis of the development of cardiovascular, metabolic, and neurodegenerative diseases, and obesity as well”.
The full text of the study can be found by clicking here. This work was funded in part by the National Science Centre of Poland.